CN115317574A - Composition for treating hyperuricemia and application thereof - Google Patents
Composition for treating hyperuricemia and application thereof Download PDFInfo
- Publication number
- CN115317574A CN115317574A CN202211009450.8A CN202211009450A CN115317574A CN 115317574 A CN115317574 A CN 115317574A CN 202211009450 A CN202211009450 A CN 202211009450A CN 115317574 A CN115317574 A CN 115317574A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- hyperuricemia
- seeds
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 60
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 21
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 21
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 21
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 21
- 241001474374 Blennius Species 0.000 claims abstract description 20
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 20
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 19
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 19
- 235000004347 Perilla Nutrition 0.000 claims abstract description 19
- 244000197580 Poria cocos Species 0.000 claims abstract description 19
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 19
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 18
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 17
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 244000088415 Raphanus sativus Species 0.000 claims abstract description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 241000675108 Citrus tangerina Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 235000009508 confectionery Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 10
- 241000219784 Sophora Species 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 241000282461 Canis lupus Species 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 238000004513 sizing Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 53
- 210000004369 blood Anatomy 0.000 abstract description 52
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 44
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 42
- 229940116269 uric acid Drugs 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 34
- 230000001603 reducing effect Effects 0.000 abstract description 26
- 230000003750 conditioning effect Effects 0.000 abstract description 11
- 244000046101 Sophora japonica Species 0.000 abstract description 10
- 235000010586 Sophora japonica Nutrition 0.000 abstract description 10
- 230000037356 lipid metabolism Effects 0.000 abstract description 10
- 230000037353 metabolic pathway Effects 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 3
- 238000013461 design Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 30
- 208000026435 phlegm Diseases 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 28
- 239000003921 oil Substances 0.000 description 24
- 235000019198 oils Nutrition 0.000 description 23
- 230000006870 function Effects 0.000 description 20
- 230000007812 deficiency Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 238000011160 research Methods 0.000 description 16
- 241000220259 Raphanus Species 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 241001092040 Crataegus Species 0.000 description 13
- 206010020772 Hypertension Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 11
- -1 phthalide compound Chemical class 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000022558 protein metabolic process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- MKMCJLMBVKHUMS-UHFFFAOYSA-N 6-Methoxybenzoxazolin-2(3H)-one Natural products COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960004699 valsartan Drugs 0.000 description 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- XNODZYPOIPVPRF-CGWDHHCXSA-N (2s)-2-methyl-4-[(2r,8r,13r)-2,8,13-trihydroxy-13-[(2r,5r)-5-[(1r)-1-hydroxytridecyl]oxolan-2-yl]tridecyl]-2h-furan-5-one Chemical compound O1[C@@H]([C@H](O)CCCCCCCCCCCC)CC[C@@H]1[C@H](O)CCCC[C@H](O)CCCCC[C@@H](O)CC1=C[C@H](C)OC1=O XNODZYPOIPVPRF-CGWDHHCXSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ZXJJBDHPUHUUHD-UHFFFAOYSA-N 4',5,7-Trimethoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OC)C=C2O1 ZXJJBDHPUHUUHD-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000276331 Citrus maxima Species 0.000 description 2
- 235000001759 Citrus maxima Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000002468 fat body Anatomy 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- HDDLVZWGOPWKFW-UHFFFAOYSA-N trimethyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound COC(=O)CC(O)(C(=O)OC)CC(=O)OC HDDLVZWGOPWKFW-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- YUTUUOJFXIMELV-UHFFFAOYSA-N 2-Hydroxy-2-(2-methoxy-2-oxoethyl)butanedioic acid Chemical compound COC(=O)CC(O)(C(O)=O)CC(O)=O YUTUUOJFXIMELV-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- NZPSYYOURGWZCM-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical group C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)C(CCCC)=NC21CCCC2 NZPSYYOURGWZCM-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- OMIHCBSQSYMFDP-UHFFFAOYSA-N 3-hydroxy-5-methoxy-3-methoxycarbonyl-5-oxopentanoic acid Chemical compound COC(=O)CC(O)(CC(O)=O)C(=O)OC OMIHCBSQSYMFDP-UHFFFAOYSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000031023 Amana edulis Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- HVFIEGOJQDOBGC-UHFFFAOYSA-N Annoglacin A Natural products O1C(C(O)CCCCCCCCCCCC)CCC1C(O)CCCCC(O)CCCCCCCC(O)CC1=CC(C)OC1=O HVFIEGOJQDOBGC-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- RSDDHGSKLOSQFK-PTNGSMBKSA-N Auraptene Natural products C1=CC(=O)OC2=CC(OC\C=C(C)/CCC=C(C)C)=CC=C21 RSDDHGSKLOSQFK-PTNGSMBKSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 244000089759 Fortunella margarita Species 0.000 description 1
- 235000019123 Fortunella margarita Nutrition 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001299895 Microsporum ferrugineum Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019057 Raphanus caudatus Nutrition 0.000 description 1
- 235000011380 Raphanus sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 241000220690 Sargassum pallidum Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PBWOIPCULUXTNY-UHFFFAOYSA-N Sitosterylacetat Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 PBWOIPCULUXTNY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- ISQRJFLLIDGZEP-KJRRRBQDSA-N Sophoricoside Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1 ISQRJFLLIDGZEP-KJRRRBQDSA-N 0.000 description 1
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- XNODZYPOIPVPRF-BGXDYLHZSA-N annonacin A Natural products O=C1C(C[C@H](O)CCCCC[C@H](O)CCCC[C@H](O)[C@H]2O[C@H]([C@H](O)CCCCCCCCCCCC)CC2)=C[C@H](C)O1 XNODZYPOIPVPRF-BGXDYLHZSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- RSDDHGSKLOSQFK-RVDMUPIBSA-N auraptene Chemical compound C1=CC(=O)OC2=CC(OC/C=C(C)/CCC=C(C)C)=CC=C21 RSDDHGSKLOSQFK-RVDMUPIBSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960005400 bisoprolol fumarate Drugs 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N isobenzofuranone Natural products C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- MUMCCPUVOAUBAN-UHFFFAOYSA-N liriodenine Chemical compound C1=NC(C(=O)C=2C3=CC=CC=2)=C2C3=C(OCO3)C3=CC2=C1 MUMCCPUVOAUBAN-UHFFFAOYSA-N 0.000 description 1
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229940036965 saxagliptin and dapagliflozin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition for treating hyperuricemia and application thereof, wherein the composition comprises 110-310 parts of diglyceride oil, 5-15 parts of exocarpium citri rubrum, 5-15 parts of poria cocos, 10-30 parts of Chinese yam, 10-20 parts of coix seeds, 5-15 parts of perilla seeds, 5-15 parts of radish seeds, 10-20 parts of seaweed, 10-30 parts of hawthorn, 5-15 parts of kudzu roots, 5-15 parts of sophora japonica and 20-50 parts of lotus leaves. The novel food raw material diglyceride oil with the special pearl metabolic pathway and the lipid metabolism conditioning function is added to the formula of the composition, the effect of reducing the blood uric acid of a medicine-food homologous formula can be cooperated, the combination of traditional Chinese medicine and modern pharmacology avoids that the existing medicine can only treat the hyperuricemia and can condition the whole body, the formula screening design is carried out according to the mouthfeel of hyperuricemia people so as to enhance the edible compliance of patients, the consideration of both the principal and secondary aspects is realized, and the hyperuricemia and the complications thereof are improved.
Description
Technical Field
The invention relates to the field of hyperuricemia treatment, and in particular relates to a composition for treating hyperuricemia and application thereof.
Background
Hyperuricemia is a common biochemical abnormality, and refers to that under the normal purine diet state, the level of non-twice-daily fasting blood uric acid is higher than 420mmol/L in men and higher than 360mmol/L in women, namely, the hyperuricemia is called. 420mmol/L and 360mmol/L are saturated concentrations of uric acid in blood of male and female populations, respectively, above which urate can be deposited in various tissues such as kidney, joint synovium, causing tissue damage.
The blood uric acid is increased, and urate can be deposited on joints to form gouty arthritis; precipitating in kidney to form gouty nephropathy and uremia; the vascular wall is stimulated to cause atherosclerosis, and coronary heart disease and hypertension are aggravated; pancreatic B cells are damaged, inducing or exacerbating diabetes. Hyperuricemia is the basis of gout, and the higher the blood uric acid level is, the higher the possibility of gout in the next 5 years is; a plurality of epidemiological studies prove that the blood uric acid is an independent risk factor of the hypertension, and the relative risk of the hypertension is increased by 25 percent for every 59.5 mu mol/L increase of the blood uric acid level. Clinical studies find that 90% of patients with primary hypertension have hyperuricemia; long-term hyperuricemia can destroy pancreatic beta cell function to induce diabetes, and researches prove that the long-term hyperuricemia has a causal relationship with sugar tolerance abnormality and diabetes onset; the epidemiological data at home and abroad show that the blood uric acid and the triglyceride are related, and a prospective queue research on the relationship between the uric acid and the triglyceride finds that the basic triglyceride is an independent prediction factor of the future hyperuricemia; the pathophysiological basis of the metabolic syndrome is hyperinsulinemia and insulin resistance, the insulin resistance enables the generation of blood uric acid to be increased in the glycolysis process and the free fatty acid metabolism process, hyperuricemia is directly caused by increasing the reabsorption of uric acid by the kidney, and 70% of patients with the metabolic syndrome are simultaneously combined with the hyperuricemia; research shows that uric acid is an independent risk factor for coronary heart disease death of the general population regardless of sex. When the blood uric acid rises by 1mg/dl, the death risk is increased by 48 percent in males and 126 percent in females. Blood uric acid >6mg/dl is an independent risk factor for coronary heart disease; blood uric acid >7mg/dl is an independent risk factor for stroke; many epidemiological investigations and animal studies have shown that uric acid can directly cause microangiopathy of the glomerular arteriole, leading to chronic kidney disease.
Therefore, the modern medicine needs a composition for treating hyperuricemia and reducing the uric acid content of a human body under pathological conditions. However, in the prior art, including chemical drugs and traditional Chinese medicines, for example, patent CN111617072A provides an application of phthalide compound and pharmaceutically acceptable salts, esters, prodrugs, solvates, polymorphs, hydrates or derivatives thereof in combination with hyperuricemia drugs in preparation of combined drugs for treating hyperuricemia, the chemical drugs have good effect of reducing uric acid, but have obvious side effects and poor compliance, can only treat hyperuricemia, cannot perform whole body conditioning, do not significantly reduce the incidence rate of complications, and are contraindicated in combination, and are not suitable for being used in cooperation with other complications treatment drugs, and cannot relieve symptoms of diabetes, hypertension and the like of patients. For example, patent CN101199750B discloses a Chinese medicinal composition comprising five Chinese medicinal herbs of glabrous greenbrier rhizome, sevenlobed yam rhizome, edible tulip, cowherb seed and twotooth achyranthes root, which has no significant effect of reducing uric acid and is also not suitable for being used in combination with other complications treatment medicines.
Disclosure of Invention
Aiming at the technical defects, the invention aims to provide a composition for treating hyperuricemia and application thereof.
According to the research result, in order to solve the prior technical problem, the invention adopts the following technical scheme:
the invention aims to provide a composition for treating hyperuricemia, which comprises the following raw materials in parts by mass: 110-310 parts of diglyceride oil, 5-15 parts of tangerine peel, 5-15 parts of poria cocos, 10-30 parts of Chinese yam, 10-20 parts of coix seeds, 5-15 parts of perilla seeds, 5-15 parts of radish seeds, 10-20 parts of seaweed, 10-30 parts of hawthorn, 5-15 parts of kudzu roots, 5-15 parts of sophora flower buds and 20-50 parts of lotus leaves.
Further, 132-248 parts of diglyceride oil, 6-12 parts of tangerine peel, 6-12 parts of poria cocos, 15-25 parts of Chinese yam, 12-18 parts of coix seeds, 6-12 parts of perilla seeds, 6-12 parts of radish seeds, 12-18 parts of seaweed, 15-25 parts of hawthorn, 6-12 parts of kudzu roots, 6-12 parts of sophora flower buds and 20-30 parts of lotus leaves.
Further, the traditional Chinese medicine composition comprises 240 parts of diglyceride oil, 10 parts of tangerine peel, 10 parts of poria cocos, 20 parts of Chinese yam, 15 parts of coix seeds, 10 parts of perilla seeds, 10 parts of radish seeds, 15 parts of seaweed, 20 parts of hawthorn, 10 parts of kudzu roots, 10 parts of sophora japonica and 30 parts of lotus leaves.
The second purpose of the invention is to provide the application of the composition for treating hyperuricemia in medicines for treating hyperuricemia.
Further, the dosage form of the composition comprises tablets, pills, granules, capsules, soft capsule preparations, liquid preparations or gel candies.
The third purpose of the invention is to provide a preparation method of the composition for treating hyperuricemia, which comprises the steps of weighing medicinal and edible medicinal materials in the formula according to the mass parts, carrying out water extraction, concentration, drying and crushing on the medicinal and edible medicinal materials to prepare extract powder, sieving the extract powder by a 200-mesh sieve, and adding the extract powder into new food raw material diglyceride oil to prepare the composition.
Further, the gelatin, the glycerol, the sorbitol solution and other components are added into the composition, and the gel candy is prepared by the processes of batching, pressing, shaping, drying, sorting and packaging.
Modern medicine considers that disorders of lipid metabolism and protein metabolism (purine metabolism) are major causes of hyperuricemia, and are related to factors such as age, sex, and life. The traditional Chinese medicine considers that spleen qi deficiency and phlegm-blood stasis are the main pathogenesis of the disease.
Because the formation mechanism of hyperuricemia is complex and easy to react repeatedly, the curative effect of the existing medicament for reducing the blood uric acid in clinical use is not satisfactory, and the existing medicament has larger side effect, and the actual curative effect of the western medicine in the clinical treatment of the hyperuricemia is difficult to achieve the ideal condition. Lifestyle intervention is therefore the first measure to regulate purine metabolic disorders. Lifestyle modifications (including healthy diet, adherence to exercise and weight control, etc.), appropriate dietary conditioning, pharmacological intervention and health education management are currently common means for preventing and treating disorders of purine metabolism.
The traditional Chinese medicine has no traditional Chinese medicine names which completely correspond to the hyperuricemia in the traditional Chinese medicine, the hyperuricemia is simply classified into gout, arthralgia, fever with tiger, pyretic fever and the like, and the majority of hyperuricemia patients have no obvious symptoms from the syndrome differentiation condition of clinical patients, and the blood uric acid level is higher than the normal value only by physical examination.
The traditional Chinese medicine considers that hyperuricemia is the syndrome of principal deficiency and secondary excess, and is mainly caused by deficiency of spleen and kidney, liver and kidney deficiency, essence and blood deficiency, damp turbidity, blood stasis and blocking of channels and collaterals due to natural deficiency, or overstrain, cold and heat imbalance, diet loss (excessive drinking, eating) and the like. Or stagnation in channels can cause swelling and pain of bone joint, calculus malformation, even rupture, and fat leakage; or stagnation transforming into heat, accumulating into toxicity and damaging spleen and kidney. Therefore, deficiency of liver and kidney and dysfunction of spleen in transportation and transportation are the primary symptoms of the disease, and stagnation of turbid phlegm is the secondary symptom of the disease. In general, the pathogenesis of this disease is no external dampness, phlegm, heat, stasis or deficiency of the five extremities, while the affected viscera are heavily located in the liver, spleen and kidney. The literature on treating hyperuricemia shows that the traditional Chinese medicine has the symptoms of turbid phlegm and blood stasis, long-term phlegm and blood stasis blocking collaterals, insufficiency of yang qi and deficiency of liver and kidney.
The traditional Chinese medicine carries out comprehensive syndrome differentiation treatment from the overall view and the preventive treatment of diseases, regulates metabolism and corrects the source thereof, clears heat and promotes diuresis to treat the symptoms thereof, dissolves turbidity and breaks stasis to dredge channels and collaterals, and regulates and tonifies liver and kidney to consolidate the basis, and the traditional Chinese medicine is applied to patients with hyperuricemia to achieve good effect.
The invention applies the theory of traditional Chinese medicine physique and combines the research result of the identification relationship between hyperuricemia and traditional Chinese medicine physique. Constitutions are inherent characteristics of the human body which are relatively stable in function and form and are expressed on the basis of heredity and acquirement, but are also adjustable. The theory related to physical diseases of the theory of constitutions of traditional Chinese medicine says that the purpose of treating related diseases can be achieved through conditioning and intervening constitutions. From the research results of the relationship between traditional Chinese medicine physique and hyperuricemia, patients with hyperuricemia are not always in phlegm-dampness physique, people belonging to the phlegm-dampness physique do not all suffer from hyperuricemia, but the population with the phlegm-dampness physique is a high-incidence population with the hyperuricemia, the probability of suffering from the hyperuricemia is far higher than that of a common person, and the research shows that 84.5 percent of the traditional Chinese medicine physique of the population with the hyperuricemia is in the phlegm-dampness physique, so that the hyperuricemia can be treated by conditioning the phlegm-dampness physique.
Meanwhile, by combining the theory of metabolism of three nutrients of a human body, the fact that lipid metabolism can influence the metabolism of proteins and saccharides is considered, the content of purine substances which are metabolic intermediates is higher due to the disturbance of protein metabolism (amino acid metabolism), and the content of uric acid in blood is abnormal due to the excessive production of uric acid by purine after being oxidized by liver, so that hyperuricemia is caused, so that the regulation of hyperuricemia caused by purine metabolic abnormality by regulating lipid metabolism is a basis of modern medicine. In conclusion, the new resource food raw material diglyceride oil with the special pearl metabolic pathway and the lipid metabolism conditioning function is added to the formula in clinical experiments, the action of reducing the blood uric acid of the medicine-food homologous formula can be cooperated, and the traditional Chinese medicine and the modern pharmacology are combined to realize the consideration of both the symptoms and root causes.
The diglyceride oil (DAG) in the formula is a new food raw material approved by the national ministry of health, has special bead metabolic pathway and lipid metabolism and protein metabolism regulation functions, and is shown by modern medical research and clinical experiments: diglyceride oil is effective in improving chronic metabolic syndrome disorders including lipid metabolism and purine metabolism.
The tangerine peel and the tuckahoe in the formula have the effects of tonifying spleen and qi, reducing phlegm and eliminating dampness, and are designed aiming at main pathogenesis, so the tangerine peel and the tuckahoe are monarch drugs together. The Chinese yam has the effects of tonifying spleen and qi, and modern pharmacological studies show that the Chinese yam has the effect of reducing blood sugar; the coix seeds have the effects of tonifying spleen and excreting dampness, and inducing diuresis to alleviate edema, and the perilla seeds (perilla seeds) and the radish seeds have the effects of regulating qi and reducing phlegm, and accord with the theory that the phlegm is treated first to treat qi, the phlegm rises along with the rising of qi, and the phlegm falls along with the falling of qi in the traditional Chinese medicine; the four medicines are used as ministerial medicines. The modern pharmacological research shows that fucoidan sulfate in the seaweed can reduce serum cholesterol, and in addition, the seaweed water extract has the function of reducing blood pressure; the hawthorn has the effects of tonifying spleen, stimulating appetite, promoting digestion, removing food stagnation, promoting blood circulation, removing blood stasis, expanding blood vessels, reducing blood sugar and reducing blood pressure; puerarin has obvious functions of lowering blood sugar, expanding blood vessel, lowering peripheral resistance and lowering blood pressure; modern pharmacological research shows that the sophora flower bud has obvious blood pressure lowering effect. The lotus leaf can promote diuresis and reduce blood fat. The five medicines are used as adjuvant and guiding medicines. The medicines are combined to play the roles of strengthening spleen and replenishing qi, reducing phlegm and eliminating dampness, and activating blood circulation to dissipate blood stasis.
The pharmacological actions of the compatible food materials in the formula are described as follows:
diglyceride (DAG) is a structural lipid in which one fatty acid in Triglyceride (TAG) is substituted by a hydroxyl group, is a trace component of natural vegetable fat and oil, and is a food component recognized as safe (GRAS) in the world. In 2009, the derivatives (diglyceride oil) of the edible oil are listed as national new resource foods in China, and strict quality requirement evaluation standards are established for the derivatives. Diglyceride has special metabolic path and function in vivo, and the existing toxicological evaluation results at home and abroad are safe. The scientific literature in the international publication section on the study of the health impact of diglyceride oils shows: diglycerides lower serum triglycerides by altering hepatic fatty acid metabolism; repeated eating of diglyceride can promote fat metabolism after meal and reduce visceral fat area; the consumption of diglyceride obviously improves the energy utilization rate of the dietary fat. Clinical experiments and modern research of a plurality of domestic hospitals prove that: the diglyceride oil has the functions of regulating lipid metabolism and purine metabolism, and can obviously reduce the concentration of uric acid in blood serum.
Exocarpium citri rubrum is an immature or near-mature dried outer pericarp of Osbeck, citrus grandis (L.) grandis (Citrus grandis) of Rutaceae. Pungent and bitter taste, warm in nature. It enters lung and spleen meridians. Has the functions of dispelling cold, eliminating dampness, promoting qi circulation and eliminating phlegm. Can be used for treating cough due to wind-cold evil, itching throat, excessive phlegm, food stagnation, alcohol injury, nausea, vomiting, and stuffiness. Contains volatile oil, and the main components are citral, geraniol, linalool, o-methyl carbamate, limonene, alpha-pinene, etc. And (3) flavonoid components: naringin, neohesperidin, poncirin, fortunella margarita, nobiletin, 5,7,4' -trimethoxyflavone, etc.; stachydrine, umbelliferone, auraptene, glycine, beta-sitosterol glucoside, montanane, etc. It also contains protein, fat, saccharide, carotene, vitamins B1, B2, C, nicotinic acid, etc. Modern researches have proved that the composition has effects of resisting inflammation, reducing blood viscosity, and promoting blood circulation.
Poria is dry sclerotium of Wolf of Poriacocos (Schw.) of Polyporaceae. Sweet and bland in flavor and mild in nature. Enter heart, lung, liver and kidney meridians. Has effects of promoting diuresis, eliminating dampness, invigorating spleen, and calming heart. It is used clinically in treating edema, oliguria, phlegm and fluid retention, dizziness, palpitation, spleen deficiency, anorexia, loose stool, diarrhea, uneasiness, palpitation, insomnia, etc. The main ingredients include beta-pachyman and triterpenoid such as acetylpachymic acid, pachymic acid, 3 beta-hydroxylanostadienoic acid, gum, chitin, protein, fat, sterol, lecithin, glucose, adenine, histidine, choline, beta-pachyman decomposition enzyme, lipase, protease, etc. The pharmacological verification shows that the product has the effects of resisting bacteria, promoting urination, reducing blood sugar, resisting ulcer, etc.
The rhizoma Dioscoreae is dried rhizome of Dioscorea opposita Thunb of Dioscoreaceae or Dioscorea opposita Thunb of the same genus. It enters lung, spleen and kidney meridians, and is sweet in taste and neutral in nature; has the functions of invigorating spleen and stomach, promoting the production of body fluid and benefiting lung, and tonifying kidney and arresting seminal emission. Can be used for treating spleen deficiency, anorexia, chronic diarrhea, lung deficiency, cough, asthma, spermatorrhea, leukorrhagia, frequent micturition, and diabetes due to deficiency heat. Bran-fried Chinese yam can tonify spleen and strengthen stomach. Can be used for treating spleen deficiency, anorexia, diarrhea, loose stool, and leukorrhagia. The rhizoma Dioscoreae tuber and root contains diosgenin, dopamine, cholesterol, ergosterol, campesterol, stigmasterol, beta-sitosterol, polyphenol oxidase, allantoin, estutinin, glycoprotein, lysine, histidine, arginine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, leucine, isoleucine, tyrosine, phenylalanine, methionine, polysaccharide with blood sugar lowering effect, and various microelements. Modern pharmacology proves that the traditional Chinese medicine composition has the effects of reducing blood sugar, resisting stress reaction, improving the immunity of organisms and the like.
The Coicis semen is derived from dried mature kernel of Coixlacryma-jobil of Gramineae, coicis semen Coixlacryma-yuen (Roman.) Stapf. In autumn, the fruit is ripe, the plant is cut, dried in the sun, the fruit is removed, dried in the sun again, and the shell, the tawny seed coat and impurities are removed. Coix seed, sweet and bland in taste, cool in nature, enters spleen, stomach and lung meridians. Has the functions of invigorating spleen, eliminating dampness, eliminating arthralgia, stopping diarrhea, clearing away heat and expelling pus. Can be used for treating edema, loempe, dysuresia, damp arthralgia, spasm, diarrhea due to spleen deficiency, pulmonary abscess, and intestinal abscess; flat warts, and the like. Coicis semen contains protein, fat, carbohydrate, small amount of vitamin B1, amino acids (such as leucine, lysine, arginine, tyrosine, etc.), coixol ester, and triterpene compounds. Coix seed oil or saturated fatty acids containing 10-18 carbon atoms (C) can prevent or reduce contraction of striated muscle (non-neuromuscular junction site), while unsaturated fatty acids (such as oleic acid) do not. Coix seed oil (0.5 g/kg subcutaneously injected in rabbit) and fatty acid with C number of more than 12 can reduce blood sugar, which can be antagonized by pyruvic acid, reduce serum calcium, and fatty acid with lower C number (such as capric acid) has no influence on blood sugar and blood calcium. Coix seed oil (mainly palmitic acid and its esters) is responsible for respiration, small amount of excitement, and large amount of paralysis (central); can remarkably expand pulmonary vessels. For in vitro frog heart and in vitro rabbit intestine, the low concentration shows the excitation function, the high concentration shows the inhibition function; generally has excitation effect on the uterus of rabbits and guinea pigs, and epinephrine can reverse the excitation effect; it also has diuretic effect; a large amount of the medicine can paralyze animals and stop breathing. Coixol has effects of inhibiting striated muscle, inhibiting central nerve, relieving pain, and preventing lethality of strychnine or pentaerythrine; has good heat-relieving effect on the heat caused by the compound polysaccharide refined by the thalli, but has no effect on the heat caused by the dinitrophenol. Coix seeds have been reported to have growth-arresting and injuring effects on cancer cells.
The fructus Perillae is dried mature fruit of Perilla frutescens (L.) Britt. Collected in autumn when the fruit is ripe, removed of impurities and dried in the sun. It is pungent and warm in flavor. It enters lung meridian. Has the functions of depressing qi, eliminating phlegm, relieving asthma and moistening intestines. Can be used for treating phlegm obstruction, adverse rising of qi, cough, asthma, and constipation due to intestinal dryness. Perilla contains protein, lipid sterol, etc. Wherein the oil contains fatty acid, linolenic acid, and linoleic acid; lecithin, cephalin, phosphatidylserine, and the like. The sterols are mainly beta-sitosterol. Modern researches prove that the traditional Chinese medicine composition has the effects of resisting tumors, improving learning ability, prolonging survival time of spontaneous hypertensive rats and the like.
The Raphani semen is dried mature seed of Raphanus sativus L. Harvesting plants when fruits are mature in summer, drying in the sun, rubbing out seeds, removing impurities, and drying in the sun again. Pungent and sweet in flavor and mild in nature. It enters lung, spleen and stomach meridians. Has the functions of promoting digestion, relieving flatulence, descending qi and eliminating phlegm. Can be used for treating food stagnation, abdominal distention and pain, constipation, stagnation, dysentery, phlegm stagnation, and cough and asthma. Contains protein, fatty oil, volatile oil and sinapine. The volatile oil contains methyl mercaptan, etc. The fatty oil contains high content of erucic acid, linoleic acid, linolenic acid, erucic acid glyceride, etc. Also contains antibacterial substance called sulforaphane. Modern researches prove that the traditional Chinese medicine composition has the function of resisting pathogenic microorganisms: the radish seed aqueous extract has obvious inhibiting effect on staphylococcus, escherichia coli and the like, and the water extract has inhibiting effect on trichophyton concentricum, yellow ringworm of Schwannion, microsporum austrianum, microsporum ferrugineum, microsporum lanugineum and Nocardia stellaton with different degrees. Neutralizing endotoxin, lowering blood pressure, and reducing peripheral vascular resistance.
The seaweed is dried fronds of Sargassaceae Sargassum pallidum (Turn.) C.Ag. or Sargassum fusiforme (Harv.) Setch. The former is known as "kelp", and the latter is known as "lobular seaweed". Collected in summer and autumn, cleaned and dried in the sun after removing impurities. Bitter, salty and cold. It enters liver, stomach and kidney meridians. Has the effects of softening and resolving hard mass, eliminating phlegm and inducing diuresis. It can be used for treating goiter, scrofula, swelling and pain of testis, and edema due to phlegm and fluid retention. Contains alginic acid 20.8%, crude protein 7.95%, mannitol 10.25%, ash 37.19%, potassium 12.82%, and iodine 0.03%. Modern pharmacological actions include improvement of thyroid hypofunction caused by iodine deficiency, temporary suppression of metabolic rate of hyperthyroidism, and alleviation of symptoms, but they are not durable. Iodide, after entering tissues and blood, can also promote the absorption of pathological products such as inflammatory exudates. And can cause the collapse and dissolution of diseased tissues, so it is not generally used for active tuberculosis. In addition, it has anticoagulant, blood pressure lowering, and blood lipid reducing effects.
The fructus crataegi is dried mature fruit of Crataegus Pinnatifida Bge.var.majorn.E.Br. or Crataegus Pinnatifida Bge.of Rosaceae, and is removed of impurities and shed kernel. Pungent and sweet in flavor, slightly warm in nature. Enter spleen, stomach and liver meridians. Has effects of resolving food stagnation, invigorating stomach, activating qi-flowing and removing blood stasis. The traditional Chinese medicine composition is clinically used for treating meat food stagnation, gastric cavity fullness, dysentery and abdominal pain, blood stasis and amenorrhea, postpartum blood stasis, heart and abdominal stabbing pain and hernia pain; hyperlipidemia and the like. The modern research mainly contains flavonoid and triterpenes, including L-epi-theanine, quercetin, hyperin, ursolic acid, chlorogenic acid, citric acid, monomethyl citrate, dimethyl citrate, trimethyl citrate, flavan polymer, etc. The pharmacological verification shows that the health food has the effects of promoting digestion, strengthening heart, reducing blood pressure, reducing blood fat, resisting oxidation, improving immunity and the like.
Kudzu root is dried root of Pueraria lobata (Willd.) Ohwi, a leguminous plant. Sweet, pungent and cool in nature. It enters spleen and stomach meridians. Has the functions of expelling pathogenic factors from muscles, allaying fever, promoting the production of body fluid, promoting eruption, invigorating yang and relieving diarrhea. Contains puerarin, puerarin glycoside, daidzein glycoside, beta-sitosterol, and arachidic acid. The pharmacological research has the functions of dilating coronary artery, relieving spasm, reducing blood sugar, relieving fever and the like. The traditional Chinese medicine composition is mainly clinically used for fever and headache caused by exogenous pathogens, strong pain of neck and back, thirst, diabetes, measles without adequate eruption, dysentery caused by heat and diarrhea; high blood pressure, neck and neck pain.
Flos Sophorae Immaturus is flower bud of Sophora japonica L. of Leguminosae. Collected in summer when the flower buds are formed, dried in time and removed of branches, stalks and impurities. Bitter and slightly cold in nature. It enters liver and large intestine meridians. Has the functions of cooling blood, stopping bleeding, clearing liver-fire and purging fire. Can be used for treating hematochezia, hemorrhoidal bleeding, bloody flux, metrorrhagia, hematemesis, epistaxis, liver heat with conjunctival congestion, headache, and vertigo. Contains flavonoid components such as rutin, sophora japonica Makino A, etc.; other sterols, such as sophoricoside B and C, triterpenoid saponin, betulin, sophoricediol, glucose, glucuronic acid, and tannin. Has effects in improving capillary elasticity, reducing capillary permeability, relieving inflammation, relieving spasm, resisting ulcer, dilating coronary artery, improving myocardial circulation, reducing cholesterol, and inhibiting bacteria.
The folium Nelumbinis is dried leaf of Nelumbo nucifera Gaertn of Nymphaeaceae. Collected in summer and autumn, sun-dried to seven or eight dry, removed leaf stalk, folded into semicircle or fan shape, and dried. The bitter taste is neutral, and enters liver, spleen and stomach meridians. Has the functions of clearing away summer-heat, raising the body's vital energy, cooling blood and arresting bleeding. Can be used for treating summer heat, polydipsia, summer damp diarrhea, spleen deficiency diarrhea, hematemesis, epistaxis, hematochezia, metrorrhagia, and metrostaxis. The lotus leaf charcoal astringes to remove blood stasis to stop bleeding. Can be used for treating various hemorrhagic diseases and puerperal blood fainting. The leaf contains liensine, nuciferine, protopanabasine, meyersinine, protopanabasine, N-demethylnuciferine, D-N-methylcoumarin, annonacin, liriodenine, quercetin, isoquercitrin, liensin, tartaric acid, citric acid, malic acid, gluconic acid, oxalic acid, succinic acid, and tannin. Also contains alkaline components with antimitotic effect.
Clinical study
The clinical application of the inventor on 90 patients with hyperuricemia is carried out on the dietary formula disclosed by the invention, and the effect of the dietary formula is observed by self-contrast before and after the formula is eaten. Wherein the diagnostic criteria are: it is necessary to have:
(1) BMI body mass index: male is more than or equal to 25, female is more than or equal to 23;
(2) Any two of the following 5 factors: (1) increase of uric acid: > 420. Mu. Mol/L (male) and > 360. Mu. Mol/L (female); (2) elevated Triglyceride (TG) levels: > 150mg/dl (1.70 mmol/L), or has received special treatment for this lipid abnormality; (3) reduced high density lipoprotein cholesterol (HDL-C) levels: male < 40mg/dl (1.03mm01-L), female < 50mg/dl (1.29 mmol/L) or has received special treatment for this lipid abnormality; (4) elevation of fasting blood glucose: fasting glucose is greater than or equal to 100mg/dl (5.6 mmol/L, or has been diagnosed as type 2 diabetes if fasting glucose is greater than or equal to 100mg/dl (5.6 mmol/L), the Oral Glucose Tolerance Test (OGTT) is strongly recommended, but OGTT is not necessary in diagnosing metabolic syndrome.
The treatment scheme comprises the following steps: all subjects had diet control, moderate exercise and weight loss; a low-salt and low-fat diet is adopted; moderate intensity aerobic exercise for at least 30 minutes per day; eating the gel candy prepared by the formula of the invention twice a day; patients with diabetes take metformin, patients with hypertension take captopril, valsartan amlodipine tablets and the like; the treatment course is 8-16 weeks.
And (4) observation indexes are as follows: the uric acid, the blood fat and the blood sugar are measured once before and after eating.
As a result:
index (I) | Before eating (average) | After eating (average) |
BMI | 26.85 | 26.1 |
Uric acid (mu mol/L) | 495 | 368 |
Triglyceride (mmol/L) | 1.97 | 1.63 |
Total cholesterol (mmol/L) | 4.69 | 4.02 |
LDL-C(mmol/L) | 3.11 | 2.61 |
HDL-C(mmol/L) | 1.11 | 1.15 |
Fasting blood glucose (mmol/L) | 7.34 | 6.48 |
The results show that the indexes of BMI index, uric acid, triglyceride, total cholesterol, fasting blood glucose and the like are reduced, wherein the uric acid and the triglyceride are obviously reduced, and the complications are improved. No adverse events occurred during the treatment period.
Typical clinical cases
Case 1:
huang-some, male, 71 years old. Obesity was more than 5 years, and the trial began in 6 months of 2020, BMI before the trial: 27.28kg/m 2 626 mu mol/L uric acid, fat body, heavy limbs, lassitude, easy fatigue, good sleep, pale tongue with white and greasy coating, slippery pulse, and red and swollen joints. And (3) Western diagnosis: hyperuricemia, accompanied with type 2 diabetes, hypertension, diagnosis in traditional Chinese medicine: phlegm-dampness stagnates in the spleen. The valsartan amlodipine tablets and the metformin hydrochloride tablets are used at present. The prescription of the invention is given to try to take after reasonable diet, low-purine food is taken as the main food and proper exercise is performed. After the preparation is continuously used for conditioning for 2 months, the symptoms and various physical and chemical inspection indexes are obviously improved, and the uric acid is reduced to 359 mu mol/L. Without arthritis, tophus and uric acid calculi.
Case 2:
a certain woman in the piece is aged 64 years and starts to eat in 6 months in 2020. BMI before tasting: 26.56kg/m 2 590 mu mol/L uric acid, fat body, hypodynamia, dizziness, pale red tongue, white and greasy coating and slippery pulse. The past medical history: hypertension is 10 years old, hyperlipidemia, type 2 diabetes mellitus, hyperuricemia, thyroidectomy is performed, and the traditional Chinese medicine diagnosis is as follows: syndrome of intermingled phlegm and blood stasis. And (3) Western diagnosis: metabolic syndrome, hyperuricemia, hypertension, type 2 diabetes. The traditional medicine is irbesartan hydrochlorothiazide tablets, aspirin, metformin hydrochloride, pioglitazone hydrochloride, febuxostat and Youmetone. The formula of the invention is given to eat after people order reasonable diet, drink more water and exercise properly. After 2 weeks the symptoms were significantly reduced and after 8 weeks the uric acid was reduced to 359. Mu. Mol/L.
Case 3:
plum, a certain one, male, 36 years old, starts to eat in 6 months of 2020. BMI before tasting: 37.38kg/m 2 Uric acid 700 mu mol/L, obesity, dizziness, heaviness of the limbs, white and greasy tongue coating, slippery pulse, red swelling and pain of joints. Western medicine can diagnose hyperuricemia, obesity, hyperlipidemia and hypertension. Traditional Chinese medicine diagnosis: syndrome of intermingled phlegm and blood stasis. The conventional medicaments of valsartan, nifedipine sustained release tablets, bisoprolol fumarate, ezetimibe and atorvastatin are adopted. After the formula is eaten after 3 weeks, the symptoms are obviously relieved, and after 8 weeks, the uric acid is reduced to 452 mu mol/L by repeating examination.
Case 4:
li Shi, male, 62 years old, started the trial at 3 months 2020. BMI before test diet: 26.13kg/m 2 Uric acid 510 μmol/L, overweight body, dizziness, lassitude, white and greasy tongue coating, and slippery pulse. Western medicine can diagnose hyperuricemia, accompanied with type 2 diabetes and hypertension. Traditional Chinese medicine diagnosis: phlegm-dampness stagnates in the spleen. The existing medicines of losartan potassium, nifedipine controlled release tablets, saxagliptin and dapagliflozin are adopted. After the formula is eaten after the reasonable diet and proper exercise, the symptoms are obviously relieved after 4 weeks, and after 8 weeks, the uric acid is reduced to 309 mu mol/L.
The invention has the beneficial effects that:
1. according to the composition for hyperuricemia, through the compatibility of diglyceride oil and other components, new resource food raw material diglyceride oil with special pearl metabolic pathway and lipid metabolism conditioning functions in clinical experiments is added into the formula, the uric acid reducing effect is obvious, the effect of reducing the uric acid in blood can be cooperated with a medicine-food homologous formula, and the traditional Chinese medicine and the modern pharmacology are combined to realize both the treatment of principal and subordinate symptoms; the medicine is not contraindicated when taken together with the complication medicine;
2. the invention avoids the problems that the existing medicines can only be used for treating and can be used for conditioning the whole body, particularly, the effect of treating chronic diseases such as hyperuricemia is obvious, and the traditional medicines start from conditioning phlegm-dampness constitution and regulating lipid metabolism and protein metabolism aiming at the hyperuricemia, have the effect of obvious conditioning effect while reducing uric acid, have few adverse reactions, reduce the incidence rate of complications in a targeted manner, and relieve the symptoms of diabetes, hypertension and the like of a patient;
3. the medicinal materials of the formula are medicinal and edible, the safety is high, the formula is screened and designed aiming at the mouthfeel of hyperuricemia crowds to enhance the edible compliance of patients, and the medicinal materials can be prepared into different dosage forms, so that the treatment requirements of different patients are met.
4. The composition for hyperuricemia provided by the invention is refined and safe in formula, and is particularly suitable for development of food and drug industries.
Detailed Description
The process of the present invention is described and illustrated in detail below with reference to specific examples. The content is to explain the invention and not to limit the scope of protection of the invention.
Example 1
240 parts of diglyceride oil, 10 parts of tangerine peel, 10 parts of poria cocos, 20 parts of Chinese yam, 15 parts of coix seeds, 10 parts of perilla seeds, 10 parts of radish seeds, 15 parts of seaweed, 20 parts of hawthorn, 10 parts of kudzu roots, 10 parts of sophora flower buds and 30 parts of lotus leaves are weighed according to the weight ratio.
Extracting medicinal and edible medicinal materials in the formula with water, concentrating, drying, pulverizing to obtain extract powder (sieving with 200 mesh sieve), adding into new food material diglyceride oil, and making into composition according to conventional method.
Example 2
240 parts of diglyceride oil, 15 parts of tangerine peel, 15 parts of poria cocos, 10 parts of Chinese yam, 10 parts of coix seeds, 5 parts of perilla seeds, 15 parts of radish seeds, 10 parts of seaweed, 30 parts of hawthorn, 15 parts of kudzu roots, 15 parts of sophora japonica and 20 parts of lotus leaves are weighed according to weight ratio.
The procedure was as in example 1.
Example 3
255 parts of diglyceride oil, 5 parts of tangerine peel, 5 parts of poria cocos, 30 parts of Chinese yam, 20 parts of coix seeds, 15 parts of perilla seeds, 5 parts of radish seeds, 20 parts of seaweed, 10 parts of hawthorn, 5 parts of kudzu roots, 5 parts of sophora japonica and 50 parts of lotus leaves are weighed according to weight ratio.
The procedure was as in example 1.
Example 3
220 parts of diglyceride oil, 6 parts of tangerine peel, 6 parts of poria cocos, 25 parts of Chinese yam, 12 parts of coix seeds, 12 parts of perilla seeds, 12 parts of radish seeds, 18 parts of seaweed, 15 parts of hawthorn, 12 parts of kudzu roots, 6 parts of sophora flower buds and 25 parts of lotus leaves are weighed according to the weight ratio.
The procedure was as in example 1.
Example 4
220 parts of diglyceride oil, 6 parts of tangerine peel, 6 parts of poria cocos, 25 parts of Chinese yam, 12 parts of coix seeds, 12 parts of perilla seeds, 12 parts of radish seeds, 18 parts of seaweed, 15 parts of hawthorn, 12 parts of kudzu roots, 6 parts of sophora flower buds and 25 parts of lotus leaves are weighed according to the weight ratio.
The procedure was as in example 1.
Example 5
180 parts of diglyceride oil, 9 parts of exocarpium citri rubrum, 12 parts of poria cocos, 18 parts of Chinese yam, 18 parts of coix seeds, 9 parts of perilla seeds, 9 parts of radish seeds, 12 parts of seaweed, 18 parts of hawthorn, 9 parts of kudzu roots, 12 parts of sophora japonica and 24 parts of lotus leaves are weighed according to weight ratio.
The procedure was as in example 1.
Example 6
According to the weight ratio, 210 parts of diglyceride oil, 10 parts of tangerine peel, 9 parts of poria cocos, 20 parts of Chinese yam, 15 parts of coix seeds, 10 parts of perilla seeds, 6 parts of radish seeds, 15 parts of seaweed, 20 parts of hawthorn, 9 parts of kudzu roots, 10 parts of sophora japonica and 27 parts of lotus leaves are respectively weighed.
The procedure was as in example 1.
Example 7
160 parts of diglyceride oil, 12 parts of tangerine peel, 10 parts of poria cocos, 15 parts of Chinese yam, 12 parts of coix seeds, 9 parts of perilla seeds, 12 parts of radish seeds, 12 parts of seaweed, 18 parts of hawthorn, 10 parts of kudzu roots, 9 parts of sophora japonica and 30 parts of lotus leaves are weighed according to weight ratio.
The procedure is as in example 1.
Example 8
280 parts of diglyceride oil, 10 parts of tangerine peel, 10 parts of poria cocos, 18 parts of Chinese yam, 15 parts of coix seeds, 12 parts of perilla seeds, 10 parts of radish seeds, 18 parts of seaweed, 24 parts of hawthorn, 10 parts of kudzu roots, 12 parts of sophora japonica and 20 parts of lotus leaves are weighed according to the weight ratio.
The procedure was as in example 1.
Example 9
The composition prepared in example 1 can be prepared into dosage forms such as tablets, pills, granules, capsules, soft capsule preparations, liquid preparations, gel candies and the like through dosage form design, and gelatin, glycerol, sorbitol and the like are added for adjusting the mouthfeel, and the gel candies are prepared through the processes of proportioning, pressing, sizing, drying, sorting, packaging and the like. The above-mentioned embodiments, objects, technical solutions and advantages of the present invention are further described in detail, it should be understood that the above-mentioned embodiments are only illustrative of the present invention and are not intended to limit the present invention, and any modifications, equivalents, improvements and the like made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. The composition for treating hyperuricemia is characterized by comprising the following raw materials in parts by mass: 110-310 parts of diglyceride oil, 5-15 parts of tangerine peel, 5-15 parts of poria cocos, 10-30 parts of Chinese yam, 10-20 parts of coix seeds, 5-15 parts of perilla seeds, 5-15 parts of radish seeds, 10-20 parts of seaweed, 10-30 parts of hawthorn, 5-15 parts of kudzu roots, 5-15 parts of sophora flower buds and 20-50 parts of lotus leaves.
2. The composition for treating hyperuricemia according to claim 1, wherein the diglyceride oil comprises 132-248 parts, 6-12 parts of exocarpium citri rubrum, 6-12 parts of poria cocos, 15-25 parts of Chinese yam, 12-18 parts of semen coicis, 6-12 parts of perilla seed, 6-12 parts of radish seed, 12-18 parts of seaweed, 15-25 parts of hawthorn, 6-12 parts of radix puerariae, 6-12 parts of sophora flower bud and 20-30 parts of lotus leaf.
3. The composition for treating hyperuricemia according to claim 1, wherein the diglyceride oil is 240 parts, red tangerine peel 10 parts, poria cocos wolf 10 parts, chinese yam 20 parts, coix seed 15 parts, perilla seed 10 parts, radish seed 10 parts, seaweed 15 parts, hawthorn fruit 20 parts, kudzu root 10 parts, sophora flower bud 10 parts, and lotus leaf 30 parts.
4. The use of the composition of claim 1 for the treatment of hyperuricemia in a medicament for the treatment of hyperuricemia.
5. The composition for use in the medicine for treating hyperuricemia according to claim 4, wherein the dosage form of the composition comprises tablets, pills, granules, capsules, soft capsule preparations, liquid preparations and gel candies.
6. The preparation method of the composition for treating hyperuricemia according to claim 1, characterized by weighing the medicinal materials with homology of medicine and food in the formula according to the mass parts, extracting with water, concentrating, drying, crushing to obtain extract powder, sieving with a 200-mesh sieve, and adding into new food raw material diglyceride oil to prepare the composition.
7. The method for preparing a composition for treating hyperuricemia according to claim 6, wherein the composition is added with a solution comprising gelatin, glycerin and sorbitol, and is prepared into the gel candy through the processes of batching, pressing, sizing, drying, sorting and packaging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211009450.8A CN115317574A (en) | 2022-08-19 | 2022-08-19 | Composition for treating hyperuricemia and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211009450.8A CN115317574A (en) | 2022-08-19 | 2022-08-19 | Composition for treating hyperuricemia and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115317574A true CN115317574A (en) | 2022-11-11 |
Family
ID=83925768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211009450.8A Pending CN115317574A (en) | 2022-08-19 | 2022-08-19 | Composition for treating hyperuricemia and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115317574A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116746680A (en) * | 2023-06-17 | 2023-09-15 | 广东善百年特医食品有限公司 | Uric acid-reducing gout-relieving diglyceride composition and preparation method and application thereof |
CN117100836A (en) * | 2023-10-16 | 2023-11-24 | 健码制药(广东)有限公司 | Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441388A (en) * | 2016-05-30 | 2017-12-08 | 王停 | A kind of Chinese medicinal formulae for the conditioning of phlegm-dampness constitution metabolic syndrome |
-
2022
- 2022-08-19 CN CN202211009450.8A patent/CN115317574A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441388A (en) * | 2016-05-30 | 2017-12-08 | 王停 | A kind of Chinese medicinal formulae for the conditioning of phlegm-dampness constitution metabolic syndrome |
Non-Patent Citations (1)
Title |
---|
张瑛毓等: "具有降尿酸功效的食品研究进展" * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116746680A (en) * | 2023-06-17 | 2023-09-15 | 广东善百年特医食品有限公司 | Uric acid-reducing gout-relieving diglyceride composition and preparation method and application thereof |
CN117100836A (en) * | 2023-10-16 | 2023-11-24 | 健码制药(广东)有限公司 | Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue |
CN117100836B (en) * | 2023-10-16 | 2024-01-26 | 健码制药(广东)有限公司 | Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2747904C (en) | Compositions and methods for promoting weight loss and increasing energy | |
CN115317574A (en) | Composition for treating hyperuricemia and application thereof | |
CN101253903B (en) | Health food with fat-reducing function and its preparation | |
CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
JP2003192605A (en) | Lipase inhibitant | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
CN114159529A (en) | Composition for preventing and treating hypertension and preparation method thereof | |
KR20090021644A (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
KR101456937B1 (en) | Composition comprising the extracts of natural material for controling or treating obesity | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
CN1127349C (en) | Antilipemic slimming tea prepn | |
CN112843172A (en) | Chinese and western medicinal composition for improving human body function and discharging harmful toxin, and its preparation method | |
CN109394977B (en) | Traditional Chinese medicine composition with blood fat reducing function and preparation method and application thereof | |
TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
CN103932176B (en) | Health-care food composition for assisting to lower blood flat, as well as preparation method and application of composition | |
CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
CN109364202B (en) | Composition and preparation method and application thereof | |
CN103525640B (en) | Energy-keeping yang-tonifying wine | |
CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
CN107441460A (en) | The Chinese medicinal formulae that a kind of yang-deficiency constitution crowd being used for using chilly as primary symptom nurses one's health | |
CN103798475B (en) | Chinese herbal medicine honey tea (sugar-free particles) for improving sub-health status of perimenopause and preparation technology thereof | |
CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |